{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fbispecific-antibodies-in-r-r-mm-CAsMd17_","width":444,"version":"1.0","type":"rich","title":"Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/ad4591a4-528c-4e36-b846-0e828797888c/7231-podcast-1-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/7e6bbda6-bbed-4b1a-8e7e-f3cebfebe696\" height=\"200\" width=\"100%\" title=\"Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Caitlin Costello, MD, discusses the role and safety of bispecific antibodies approved for the treatment of relapsed/refractory multiple myeloma as well as emerging data and clinical trials with this treatment approach."}